Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

507.14 

5.95 1.2%

as of May 12 '21

52 Week Range:

441.00 664.64


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 5.90
4.61
12.80
16.95
24.91
31.50
42.36
56.23
72.18
95.25
94.67
growth rate -21.9% 177.7% 32.4% 47.0% 26.5% 34.5% 32.7% 28.4% 32.0% -0.6%
Earnings BIT -104.47
-222.89
414.42
713.36
798.61
1,239.34
1,330.70
2,079.60
2,534.40
2,245.00
3,294.90
growth rate 0.0% 100.0% 72.1% 12.0% 55.2% 7.4% 56.3% 21.9% -11.4% 46.8%
Avg.PE -20.80
-20.80
26.32
71.94
131.07
74.86
52.24
31.54
27.54
18.45
14.98
growth rate 0.0% 100.0% 173.3% 82.2% -42.9% -30.2% -39.6% -12.7% -33.0% -18.8%
ROA -11.41
-18.38
44.08
16.87
10.20
13.42
14.23
15.23
23.85
15.94
21.98
growth rate 0.0% 100.0% -61.7% -39.5% 31.6% 6.0% 7.0% 56.6% -33.2% 37.9%
ROE -22.60
-43.76
86.68
26.54
15.49
20.53
22.10
22.63
32.81
21.32
31.77
growth rate 0.0% 100.0% -69.4% -41.6% 32.5% 7.7% 2.4% 45.0% -35.0% 49.0%
ROIC -15.32
-24.93
59.43
21.85
13.65
18.37
19.85
20.84
30.30
20.14
27.94
growth rate 0.0% 100.0% -63.2% -37.5% 34.6% 8.1% 5.0% 45.4% -33.5% 38.7%
Cur. Ratio 3.28
4.40
7.37
6.01
3.31
3.59
2.56
3.82
4.47
3.67
3.63
growth rate 34.2% 67.5% -18.5% -44.9% 8.5% -28.7% 49.2% 17.0% -17.9% -1.1%
Quick Ratio 3.14
4.25
6.12
5.31
2.93
3.09
2.13
2.98
3.50
2.81
2.86
growth rate 35.4% 44.0% -13.2% -44.8% 5.5% -31.1% 39.9% 17.5% -19.7% 1.8%
Leverage 2.06
2.72
1.67
1.51
1.52
1.53
1.57
1.43
1.34
1.33
1.56
growth rate 32.0% -38.6% -9.6% 0.7% 0.7% 2.6% -8.9% -6.3% -0.8% 17.3%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 93.10
103.04
841.25
999.64
976.37
1,467.79
1,611.62
2,045.60
2,272.00
2,785.60
4,114.70
growth rate 10.7% 716.5% 18.8% -2.3% 50.3% 9.8% 26.9% 11.1% 22.6% 47.7%
Acct.Payable 95.63
111.35
250.90
483.49
644.11
134.98
178.20
218.20
418.10
475.50
growth rate 16.4% 125.3% 92.7% 33.2% -79.0% 32.0% 22.5% 91.6% 13.7%
Cur.Assets 357.60
665.78
1,206.01
1,796.93
2,084.76
2,915.10
3,180.19
4,335.00
6,447.60
7,689.10
9,779.10
growth rate 86.2% 81.1% 49.0% 16.0% 39.8% 9.1% 36.3% 48.7% 19.3% 27.2%
Total Assets 1,089.40
1,323.58
2,080.49
2,951.01
3,837.67
5,609.13
6,973.47
8,764.30
11,734.50
14,805.20
17,163.30
growth rate 21.5% 57.2% 41.8% 30.1% 46.2% 24.3% 25.7% 33.9% 26.2% 15.9%
Cash 112.60
483.61
230.28
535.61
648.72
809.10
535.20
812.70
1,467.70
1,617.80
2,193.70
growth rate 329.5% -52.4% 132.6% 21.1% 24.7% -33.9% 51.9% 80.6% 10.2% 35.6%
Inventory 1.42
14.65
28.64
70.35
128.86
238.58
399.36
726.10
1,151.20
1,415.50
1,916.60
growth rate 931.7% 95.5% 145.7% 83.2% 85.1% 67.4% 81.8% 58.6% 23.0% 35.4%
Cur.Liabilities 109.10
148.27
163.55
298.84
654.66
811.16
1,241.50
1,135.50
1,442.80
2,096.60
2,697.40
growth rate 35.9% 10.3% 82.7% 119.1% 23.9% 53.1% -8.5% 27.1% 45.3% 28.7%
Liabilities 561.60
837.85
835.11
998.94
1,287.42
1,954.30
2,524.22
2,620.20
2,977.20
3,715.50
6,138.00
growth rate 49.2% -0.3% 19.6% 28.9% 51.8% 29.2% 3.8% 13.6% 24.8% 65.2%
LT Debt 159.40
275.02
455.95
504.57
457.71
362.92
351.57
703.45
708.50
713.90
1,978.50
growth rate 72.5% 65.8% 10.7% -9.3% -20.7% -3.1% 100.1% 0.7% 0.8% 177.1%
Equity 527.80
485.73
1,245.39
1,952.08
2,550.25
3,654.84
4,449.25
6,144.10
8,757.30
11,089.70
11,025.30
growth rate -8.0% 156.4% 56.7% 30.6% 43.3% 21.7% 38.1% 42.5% 26.6% -0.6%
Common Shares 83.00
91.00
115.00
111.00
113.00
115.00
116.00
116.00
114.00
114.00
115.00
growth rate 9.6% 26.4% -3.5% 1.8% 1.8% 0.9% 0.0% -1.7% 0.0% 0.9%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 99.69
57.22
49.34
156.32
333.01
677.93
511.90
272.60
383.10
429.60
614.60
growth rate -42.6% -13.8% 216.9% 113.0% 103.6% -24.5% -46.8% 40.5% 12.1% 43.1%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA 99.20
-141.68
-74.62
588.60
752.44
1,330.78
1,485.90
1,307.10
2,195.10
2,430.00
2,618.10
growth rate -100.0% 0.0% 100.0% 27.8% 76.9% 11.7% -12.0% 67.9% 10.7% 7.7%
FCF per Share -0.04
-2.38
-1.07
2.49
4.90
5.40
7.21
6.92
14.14
17.39
13.68
growth rate 0.0% 0.0% 100.0% 96.8% 10.2% 33.5% -4.0% 104.3% 23.0% -21.3%
Sale Purchase of Stock 137.39
63.55
57.39
-168.51
-367.13
-516.63
240.21
110.10
-64.10
-3,271.60
growth rate -53.7% -9.7% -100.0% 0.0% 0.0% 100.0% -54.2% -100.0% 0.0%
FCF -3.00
-199.00
-124.00
427.00
410.00
653.00
961.00
1,034.00
1,812.00
2,000.00
2,004.00
growth rate 0.0% 0.0% 100.0% -4.0% 59.3% 47.2% 7.6% 75.2% 10.4% 0.2%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 459.10
445.82
1,378.48
2,104.75
2,819.56
4,103.73
4,860.40
5,872.20
5,145.60
6,557.60
8,310.40
growth rate -2.9% 209.2% 52.7% 34.0% 45.6% 18.4% 20.8% -12.4% 27.4% 26.7%
Op.Income -97.50
-221.76
750.27
413.74
823.92
1,251.92
1,330.70
2,079.60
2,534.40
2,245.00
3,294.90
growth rate 0.0% 100.0% -44.9% 99.1% 52.0% 6.3% 56.3% 21.9% -11.4% 46.8%
IBT -104.50
-222.89
414.42
696.38
761.24
1,225.10
1,329.80
2,078.50
2,553.50
2,429.10
3,810.40
growth rate 0.0% 100.0% 68.0% 9.3% 60.9% 8.6% 56.3% 22.9% -4.9% 56.9%
Net Income -104.50
-221.76
750.27
413.74
338.13
636.06
895.50
1,198.50
2,444.40
2,115.80
3,513.20
growth rate 0.0% 100.0% -44.9% -18.3% 88.1% 40.8% 33.8% 104.0% -13.4% 66.1%
EPS -1.26
-2.45
6.75
3.72
2.98
5.52
7.70
10.34
21.29
18.46
30.52
growth rate 0.0% 100.0% -44.9% -19.9% 85.2% 39.5% 34.3% 105.9% -13.3% 65.3%
Gross Profit 457.00
441.61
1,294.02
1,949.39
2,614.54
3,711.02
2,508.40
3,400.00
3,259.30
3,342.50
4,455.50
growth rate -3.4% 193.0% 50.7% 34.1% 41.9% -32.4% 35.5% -4.1% 2.6% 33.3%
R&D 489.30
529.51
625.55
859.95
1,271.35
1,620.58
2,052.30
2,735.00
2,186.10
3,036.60
2,735.00
growth rate 8.2% 18.1% 37.5% 47.8% 27.5% 26.6% 33.3% -20.1% 38.9% -9.9%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT 675.70
700.10
656.40
1,053.10
885.30
growth rate 3.6% -6.2% 60.4% -15.9%
Balance Sheet Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 2,672.20
2,933.20
2,811.30
4,039.50
4,114.70
growth rate 9.8% -4.2% 43.7% 1.9%
Acct.Payable 1,504.90
347.80
380.10
443.10
475.50
growth rate -76.9% 9.3% 16.6% 7.3%
Cur.Assets 7,689.10
8,644.10
7,860.20
9,097.60
9,779.10
growth rate 12.4% -9.1% 15.7% 7.5%
Total Assets 14,805.20
15,757.50
14,428.70
16,084.00
17,163.30
growth rate 6.4% -8.4% 11.5% 6.7%
Cash 1,617.80
2,208.20
1,992.20
1,573.00
2,193.70
growth rate 36.5% -9.8% -21.0% 39.5%
Inventory 1,415.50
1,480.90
1,640.90
1,801.60
1,916.60
growth rate 4.6% 10.8% 9.8% 6.4%
Cur.Liabilities 2,096.60
2,055.20
3,702.40
2,337.80
2,697.40
growth rate -2.0% 80.2% -36.9% 15.4%
Liabilities 3,715.50
3,624.50
5,371.30
5,958.50
6,138.00
growth rate -2.5% 48.2% 10.9% 3.0%
LT Debt 713.90
715.20
1,978.30
1,978.50
growth rate 0.2% 66.3% 0.0%
Equity 11,089.80
12,133.00
9,057.40
10,125.50
11,025.30
growth rate 9.4% -25.4% 11.8% 8.9%
Common Shares 114.30
0.10
0.10
0.10
0.10
growth rate -99.9% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures 139.00
170.10
129.90
153.20
161.40
growth rate 22.4% -23.6% 17.9% 5.4%
Cash Dividends
growth rate
Cash From OA 787.40
698.00
943.40
-254.30
1,231.00
growth rate -11.4% 35.2% -100.0% 100.0%
Sale Purchase of Stock -198.20
490.70
-3,696.30
211.00
-277.00
growth rate 100.0% -100.0% 100.0% -100.0%
FCF 648.40
527.90
813.50
-407.50
1,069.60
growth rate -18.6% 54.1% -100.0% 100.0%
Income Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 2,162.80
1,828.20
1,952.00
2,294.00
2,236.20
growth rate -15.5% 6.8% 17.5% -2.5%
Op.Income 675.70
700.10
656.40
1,053.10
885.30
growth rate 3.6% -6.2% 60.4% -15.9%
IBT 889.80
668.60
918.90
998.30
1,224.60
growth rate -24.9% 37.4% 8.6% 22.7%
Net Income 792.00
624.60
897.30
842.10
1,149.20
growth rate -21.1% 43.7% -6.2% 36.5%
EPS
growth rate
Gross Profit -80.50
1,027.00
954.50
1,335.40
1,138.60
growth rate 100.0% -7.1% 39.9% -14.7%
R&D 683.10
583.90
722.00
684.60
744.50
growth rate -14.5% 23.7% -5.2% 8.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (88.93)

YOY Growth Grade:

C (59.81)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 16.34 16.62 12.29
EPS / Growth 21.6% 30.52 10.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 24.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 10.0% 18.8% 18.8%
Future PE 12.29 22.06 22.06
Future EPS 79.16 170.62 170.62
Value Price
MOS %
240.52
-52.6%
930.51
83.5%
930.51
83.5%
MOS Price 120.26 465.26 465.26
IRT 9.65 7.47 7.47

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.